G., Pasternak, M., Wachter, A., Cobbett, C
MT-II is associated with reported cases of benign nevi modification (darkening) and, more rarely, with dermatological concerns (warranting dermato-oncological surveillance in at-risk subjects)
Many patients experience remarkable improvements in their skin tone and a reduction in pigmentation, with studies showing a 67.4% decrease in melasma scores after consistent treatment with 2% glutathione
Pesce, V., Fracasso, F., Cassano, P., Lezza, A
Patients should focus on: Protein prioritization at each meal (lean meats, fish, eggs, legumes, dairy) Nutrient-dense foods to meet micronutrient needs despite reduced caloric intake Regular meal timing to support consistent energy levels and help manage appetite Adequate hydration , as semaglutide can slow gastric emptying and some patients reduce fluid intake Clinicians should consider referring patients to registered dietitian nutritionists familiar with GLP-1 agonist therapy to develop individualized nutrition plans that support metabolic health during treatment
10.1016/j.gheart.2016.10.024 16 Bernabe-OrtizA.Carrillo-LarcoR
